ERBB2 and neoplasm: Of the nine non-luminal tumours within this subgroup a total of eight were fully interpretable for all the five biomarkers and were thus further subdivided into basal-like (4 of 8, 50%), non-luminal HER-2 (2 of 8, 25%) and tumours negative for all five biomarkers, 5NP, (2 of 8, 25%; Figure 5a).